Stage- and tissue-specific effect of cyclophosphamide during tooth development

Eur J Orthod. 2019 Sep 21;41(5):519-530. doi: 10.1093/ejo/cjz002.

Abstract

Objective: The aim of this study was to investigate the toxic effect of cyclophosphamide (CPA) in the development of rodent molars.

Methods: CPA was administered intraperitoneally in postnatal mice between Day 1 and Day 10, and the morphological phenotype was evaluated at Day 26 using micro-computed tomography and histological analysis, including cell proliferation and cell death analyses.

Results: M3 molars of the mice who received 100 mg/kg CPA treatment at Day 6 or M2 molars who received treatment at Day 1 resulted in tooth agenesis or marked hypoplasia. Histological observation demonstrated that CPA treatment at Day 6 resulted in shrinkage of the M3 tooth germs, with a significant reduction in the proliferation of apoptotic cells. Conversely, CPA exposure at Day 2, which occurs at around the bud stage of M3, resulted in crown and root hypoplasia, with reduced numbers of cusp and root. In addition, CPA exposure at Day 10, which is the late bell stage of M3, induced root shortening; however, it did not affect crown morphogenesis.

Limitations: The timing of CPA administration is limited to after birth. Therefore, its effect during the early stages of M1 and M2 could not be investigated.

Conclusion: Defective phenotypes were evident in both crown and roots due to the effect of CPA. Interestingly, the severity of the phenotypes was associated with the developmental stages of the tooth germs at the time of CPA administration. The cap/early bell stage is the most susceptive timing for tooth agenesis, whereas the late bell stage is predominantly affected in terms of root formation by CPA administration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / toxicity
  • Mice
  • Odontogenesis*
  • Tooth Crown
  • Tooth Germ
  • Tooth*
  • X-Ray Microtomography

Substances

  • Cyclophosphamide